Giovanni Neri
Giovanni Neri has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
A Battaglia
1 shared publicationA Mazzei
1 shared publicationAgatino Battaglia
Cattedra di Neuropsichiatria Infantile, Istituto Stella Maris, IRCCS, Pisa, Italy
1 shared publicationAngela Lin
Genetics and Teratology Unit, Massachusetts General Hospital, Boston, Massachusetts
1 shared publicationAttilio Mazzei
Consultorio Familiare dell'Università Cattolica, Naples, Italy
1 shared publicationBen A. Oostra
Department of Clinical Genetics, Erasmus University , Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 2 October 1998
- Published by Wiley in American Journal of Medical Genetics
- Vol. 79 (4) , 291-293
Nonsyndromal overgrowth in males with mild psychomotor delay
- 2 October 1998
- Published by Wiley in American Journal of Medical Genetics
- Vol. 79 (4) , 291-293
Nonsyndromal overgrowth in males with mild psychomotor delay
- 2 October 1998
- Published by Wiley in American Journal of Medical Genetics
- Vol. 79 (4) , 279-283
Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome
The Simpson‐Golabi‐Behmel syndrome (SGBS) is an overgrowth/multiple congenital anomalies/dysplasia syndrome caused by a mutant X‐linked gene. The spectrum of its clinical manifestations is broad, varying from very mild forms in carrier females to infantile lethal forms in affected males. A typically affected male will show tall stature, “coarse” face, supernumerary nipples, congenital heart defect, and generalized muscular hypotonia. Mental development is normal in most cases. There is an increased risk of neoplasia in infancy, especially Wilms tumor. The SGBS gene spans 500 kilobases in the Xq26 region and contains eight exons. It encodes an extracellular proteoglycan, designated glypican 3 (GPC3), capable of interacting with the insulin‐like growth factor IGF2. At present, only deletions of various sizes have been found in a number of affected families. Am. J. Med. Genet. 79:279–283, 1998.
- 2 October 1998
- Published by Wiley in American Journal of Medical Genetics
- Vol. 79 (4) , 279-283
Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome
The Simpson‐Golabi‐Behmel syndrome (SGBS) is an overgrowth/multiple congenital anomalies/dysplasia syndrome caused by a mutant X‐linked gene. The spectrum of its clinical manifestations is broad, varying from very mild forms in carrier females to infantile lethal forms in affected males. A typically affected male will show tall stature, “coarse” face, supernumerary nipples, congenital heart defect, and generalized muscular hypotonia. Mental development is normal in most cases. There is an increased risk of neoplasia in infancy, especially Wilms tumor. The SGBS gene spans 500 kilobases in the Xq26 region and contains eight exons. It encodes an extracellular proteoglycan, designated glypican 3 (GPC3), capable of interacting with the insulin‐like growth factor IGF2. At present, only deletions of various sizes have been found in a number of affected families. Am. J. Med. Genet. 79:279–283, 1998.
- 2 October 1998
- Vol. 79 (4) , 291-3
Nonsyndromal overgrowth in males with mild psychomotor delay.
Over the last 3 years we ascertained 42 patients for statural overgrowth and/or macrocephaly, who also had mild developmental delay. There were 39 males and three females, two of whom were sisters. In no case was tall stature a familial characteristic. Family history was unremarkable, except for the case of the two sisters. Physical examination did not demonstrate any consistent pattern of malformations or anomalies identifying a syndrome, known or unknown. Chromosomes were apparently normal and the molecular test for the fragile X syndrome yielded normal results in all cases. Muscular hypotonia, advanced bone age, and epilepsy were relatively consistent manifestations. The hypothalamus-pituitary axis seemed to be intact when tested through the blood levels of insulin-like growth factors I and II and of the insulin-like growth binding protein 3, and the excess of growth was apparently growth hormone independent. The condition comprising excessive growth, developmental delay, muscular hypotonia, absence of a consistent pattern of physical anomalies, and apparently sporadic occurrence, largely limited to males, may be heterogenous.
- 2 October 1998
- Vol. 79 (4) , 291-3
Nonsyndromal overgrowth in males with mild psychomotor delay.
Over the last 3 years we ascertained 42 patients for statural overgrowth and/or macrocephaly, who also had mild developmental delay. There were 39 males and three females, two of whom were sisters. In no case was tall stature a familial characteristic. Family history was unremarkable, except for the case of the two sisters. Physical examination did not demonstrate any consistent pattern of malformations or anomalies identifying a syndrome, known or unknown. Chromosomes were apparently normal and the molecular test for the fragile X syndrome yielded normal results in all cases. Muscular hypotonia, advanced bone age, and epilepsy were relatively consistent manifestations. The hypothalamus-pituitary axis seemed to be intact when tested through the blood levels of insulin-like growth factors I and II and of the insulin-like growth binding protein 3, and the excess of growth was apparently growth hormone independent. The condition comprising excessive growth, developmental delay, muscular hypotonia, absence of a consistent pattern of physical anomalies, and apparently sporadic occurrence, largely limited to males, may be heterogenous.
- Open Access
- 1 January 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (1) , 109-113
In Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome
Fragile X syndrome is the most frequent cause of heritable mental retardation. Most patients have a mutation in the 5′ untranslated region of the FMR1 gene, consisting of the amplification of a polymorphic (CGG)n repeat sequence, and cytogenetically express the folate-sensitive fragile site FRAXA in Xq27.3. Fragile X patients harbour an expanded sequence with >200 CGG repeats (full mutation), accompanied by methylation of most cytosines of the sequence itself and of the upstream CpG island. This abnormal hypermethylation of the promoter suppresses gene transcription, resulting in the absence of the FMR1 protein. Rare individuals of normal intelligence were shown to carry a completely or partially unmethylated full mutation and to express the FMR1 protein. Given this observation and knowing that the open reading frame of the mutated FMR1 gene is intact, we decided to investigate whether its activity could be restored in vitro by inducing DNA demethylation with 5-azadeoxycytidine (5-azadC) in fragile X patients' lymphoblastoid cells. We report that treatment with 5-azadC causes reactivation of fully mutated FMR1 genes with 300–800 repeats, as shown by the restoration of specific mRNA and protein production. This effect correlates with the extent of promoter demethylation, determined by restriction analysis with methylation-sensitive enzymes. These results confirm the critical role of FMR1 promoter hypermethylation in the pathogenesis of the fragile X syndrome, provide an additional explanation for the normal IQ of the rare males with unmethylated full mutations and pave the way to future attempts at pharmacologically restoring mutant FMR1 gene activity in vivo.
- 1 January 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (1) , 109-113
Open AccessIn Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome
Fragile X syndrome is the most frequent cause of heritable mental retardation. Most patients have a mutation in the 5′ untranslated region of the FMR1 gene, consisting of the amplification of a polymorphic (CGG)n repeat sequence, and cytogenetically express the folate-sensitive fragile site FRAXA in Xq27.3. Fragile X patients harbour an expanded sequence with >200 CGG repeats (full mutation), accompanied by methylation of most cytosines of the sequence itself and of the upstream CpG island. This abnormal hypermethylation of the promoter suppresses gene transcription, resulting in the absence of the FMR1 protein. Rare individuals of normal intelligence were shown to carry a completely or partially unmethylated full mutation and to express the FMR1 protein. Given this observation and knowing that the open reading frame of the mutated FMR1 gene is intact, we decided to investigate whether its activity could be restored in vitro by inducing DNA demethylation with 5-azadeoxycytidine (5-azadC) in fragile X patients' lymphoblastoid cells. We report that treatment with 5-azadC causes reactivation of fully mutated FMR1 genes with 300–800 repeats, as shown by the restoration of specific mRNA and protein production. This effect correlates with the extent of promoter demethylation, determined by restriction analysis with methylation-sensitive enzymes. These results confirm the critical role of FMR1 promoter hypermethylation in the pathogenesis of the fragile X syndrome, provide an additional explanation for the normal IQ of the rare males with unmethylated full mutations and pave the way to future attempts at pharmacologically restoring mutant FMR1 gene activity in vivo.